success
reisol
nasal
swab
lung
lesion
anim
specif
antibodi
respons
viru
shown
infect
anim
sarscov
prove
caus
agent
infecti
diseas
kuiken
et
al
sarscov
singlestrand
positivesens
rna
viru
phylogent
relat
coronavirus
group
despit
fact
encod
hemagglutininesteras
protein
snijder
et
al
genom
packag
togeth
nucleocapsid
protein
least
five
membran
protein
e
spike
protein
fig
region
within
protein
specif
acid
fragment
protein
correspond
residu
identifi
region
interact
cell
receptor
angiotensinconvert
enzym
li
et
al
major
neutral
antibodi
direct
region
protein
antibodi
rais
sever
acut
respiratori
syndrom
coronaviru
sarscov
first
emerg
human
popul
novemb
phylogenet
analysi
sarscov
isol
anim
indic
viru
probabl
origin
bat
transmit
first
palm
civet
subsequ
human
wet
market
southern
china
subsequ
outbreak
occur
earli
hong
kong
hanoi
toronto
singapor
could
directli
trace
back
one
index
patient
acquir
infect
guangdong
travel
hong
kong
worldwid
epidem
halt
effort
world
health
organ
respond
rapidli
threat
issu
global
alert
rigor
local
contain
effort
warn
unnecessari
travel
affect
area
creat
network
intern
expert
combat
viru
end
peopl
becam
ill
peopl
die
first
sar
epidem
sarscov
could
reemerg
caus
anoth
epidem
time
develop
effect
vaccin
remain
vital
import
although
sever
infecti
agent
includ
chlamydia
influenza
subtyp
human
metapneumoviru
consid
possibl
caus
sar
three
group
independ
report
isol
previous
unrecogn
cov
clinic
specimen
sar
patient
peiri
et
al
rota
et
al
drosten
et
al
electron
microscopi
serolog
reversetranscript
pcr
consensusand
randomprim
subsequ
sequenc
replicas
gene
ident
could
reveal
consist
demonstr
clinic
specimen
patient
diseas
healthi
control
conclus
establish
causal
role
cov
cynomolg
macaqu
inocul
sarscov
isol
diseas
macaqu
caus
sarscov
infect
patholog
similar
seen
human
patient
sar
sinc
viru
induc
highli
crossreact
neutral
antibodi
protect
newli
emerg
virus
relat
sarscov
protect
gastrointestin
respiratori
tract
absenc
signific
side
effect
given
fact
previou
outbreak
mainli
elderli
succumb
infect
special
attent
given
vaccin
abl
effici
protect
age
individu
protein
also
inhibit
sarscov
replic
vitro
relev
protect
remain
unclear
genom
also
encod
two
larg
polyprotein
divers
enzymat
activ
need
effici
replic
sever
accessori
protein
unknown
function
end
countri
report
total
probabl
case
sar
fig
pathogen
sarscov
circul
human
popul
moment
reemerg
anim
reservoir
may
like
occur
futur
mani
earli
sar
patient
guandong
epidemiolog
link
liveanim
market
trade
differ
anim
speci
test
presenc
sarslik
virus
soon
outbreak
sarslik
coronaviru
homolog
human
sarscov
detect
rtpcr
nasal
fecal
swab
palm
civet
paguma
larvata
raccoon
dog
nyctereut
procyonoid
guan
et
al
recent
studi
indic
bat
may
potenti
act
natur
reservoir
sarslik
cov
li
et
al
lau
et
al
howev
sequenc
comparison
protein
gene
bat
sarslik
cov
palm
civet
sarslik
cov
reveal
genet
homolog
subsequ
studi
tang
et
al
demonstr
approxim
bat
sampl
china
posit
cov
interestingli
cov
genet
divers
mani
bat
cov
cluster
exist
group
virus
other
form
separ
lineag
includ
virus
bat
put
group
sarscov
like
virus
cluster
put
group
consist
two
subgroup
one
bat
cov
anoth
sarscov
human
mammalian
host
howev
studi
direct
progenitor
sarscov
isol
palm
civet
identifi
major
genet
variat
protein
gene
virus
civet
cat
seem
essenti
transit
animaltohuman
transmiss
epidemiolog
figur
report
suspect
sar
case
novemb
juli
data
world
health
organ
http
countri
suspect
case
indic
patient
fact
none
sarscovinfect
children
age
year
hong
kong
requir
intens
care
mechan
ventil
ng
et
al
total
explain
comorbid
factor
similar
age
depend
mortal
seen
patient
nonvir
caus
acut
respiratori
stress
syndrom
rubenfeld
et
al
second
viru
transmiss
low
first
day
ill
peak
around
day
diseas
onset
chu
et
al
final
sever
studi
reveal
high
viral
load
nasopharyng
aspir
found
independ
predictor
mortal
hung
et
al
chu
et
al
therefor
vaccin
strategi
aim
reduc
viral
load
may
suffic
provid
clinic
benefit
first
effort
treat
sar
patient
mainli
base
use
ribavirin
corticosteroid
ribavirin
target
imp
dehydrogenas
known
long
time
broadspectrum
antivir
agent
howev
current
data
support
use
ribavirin
sar
treatment
vitro
studi
show
signific
antivir
activ
cinatl
et
al
ribavirin
enhanc
infect
sarscov
mice
barnard
et
al
hand
protect
effect
interferon
ifn
observ
preliminari
studi
sar
outbreak
loutfi
et
al
result
concord
sever
studi
note
antivir
activ
vitro
cinatl
et
al
hensley
et
al
anim
studi
show
pegyl
effect
reduc
sarscov
replic
excret
viral
antigen
express
type
pneumocyt
pulmonari
damag
cynomolg
macaqu
infect
experiment
sarscov
haagman
et
al
howev
despit
extens
literatur
report
sar
treatment
possibl
determin
whether
treatment
benefit
patient
sar
outbreak
variat
treatment
regimensparticularli
wide
rang
dose
durat
therapi
rout
administr
ribavirin
corticosteroid
clear
conclus
drawn
regard
efficaci
drug
test
stockman
et
al
event
futur
outbreak
sarscov
anoth
novel
agent
attempt
made
develop
treatment
protocol
organ
random
trial
collect
contribut
inform
standard
minimum
dataset
could
facilit
analysi
treatment
outcom
among
differ
set
stockman
et
al
humantohuman
transmiss
eventu
caus
sar
outbreak
present
evid
viru
persist
human
popul
possibl
option
reemerg
sar
includ
escap
viru
laboratori
alreadi
occur
three
occas
reemerg
viru
anim
reservoir
remain
possibl
given
viru
detect
fece
respiratori
secret
anim
inde
sarscov
reemerg
four
patient
guangdong
decemb
although
sarslik
cov
caus
milder
clinic
diseas
liang
et
al
us
nation
institut
allergi
infecti
diseas
biodefens
network
classifi
sarscov
categori
c
prioriti
pathogen
point
sarscov
could
potenti
biothreat
agent
clinic
symptom
sarscov
infect
lower
respiratori
tract
diseas
includ
fever
malais
peripher
cell
lymphocytopenia
decreas
platelet
count
prolong
coagul
profil
mildli
elev
serum
hepat
enzym
peiri
et
al
li
et
al
chest
radiographi
reveal
infiltr
subpleur
consolid
ground
glass
chang
compat
viral
pneumon
around
individu
sar
requir
manag
intens
care
unit
overal
case
fatal
rate
reach
approxim
although
main
clinic
symptom
sever
respiratori
ill
sarscov
actual
also
caus
gastrointestin
urinari
tract
infect
sarscov
detect
fece
urin
patient
electron
microscop
studi
biopsi
upper
lower
intestin
mucosa
patient
sar
confirm
presenc
viru
tissu
peiri
et
al
fecal
transmiss
prove
import
least
one
major
commun
outbreak
hong
kong
amoy
garden
patient
infect
within
day
three
featur
sar
may
relev
intervent
strategi
first
progress
age
depend
mortal
diseas
sever
observ
sar
major
sourc
transmiss
human
droplet
deposit
respiratori
epithelium
unlik
situat
sever
respiratori
viral
infect
viral
load
sarscov
upper
respiratori
tract
peak
around
day
diseas
onset
peiri
et
al
therefor
viru
transmiss
may
less
effici
first
day
ill
find
support
epidemiolog
observ
realtim
pcr
assay
detect
sarscov
first
week
specimen
lower
respiratori
tract
eg
bronchoalveolar
lavag
sputum
endotrach
aspir
nasopharyng
aspir
throat
swab
andor
serum
chan
et
al
wherea
fecal
sampl
may
show
high
viral
load
toward
end
first
week
second
week
ill
typic
case
larg
confin
adult
elderli
individu
sar
present
acut
respiratori
distress
syndrom
character
presenc
diffus
alveolar
damag
multiorgan
dysfunct
upon
autopsi
nichol
et
al
patholog
chang
lung
alveoli
like
follow
common
pathway
character
acut
phase
proteinrich
alveolar
fluid
influx
alveolar
lumina
consequ
injuri
alveolar
wall
subsequ
pneumocyt
hyperplasia
take
place
replac
loss
infect
pneumocyt
cover
denud
epitheli
basement
membran
result
restor
normal
alveolar
architectur
sever
alveolar
injuri
may
lead
fibrosi
loss
alveolar
function
protract
case
fig
hypothes
patholog
chang
observ
lung
initi
disproport
innat
immun
respons
illustr
elev
level
inflammatori
cytokin
chemokin
huang
et
al
wong
et
al
vivo
data
confirm
vitro
demonstr
sarscov
infect
induc
rang
cytokin
chemokin
divers
cell
type
law
et
al
although
vitro
studi
argu
product
type
ifn
inhibit
delay
sarscov
sarscovinfect
macaqu
also
earli
sar
human
type
ifn
readili
demonstr
de
lang
et
al
prophylact
treatment
macaqu
pegyl
reduc
sarscov
replic
lung
regul
product
ifn
may
import
control
sar
haagman
et
al
base
observ
sarscov
infect
effici
control
upon
passiv
transfer
antibodi
direct
protein
sarscov
rang
vaccin
contain
proteingen
develop
anim
immun
inactiv
whole
viru
vaccin
liverecombin
vaccin
express
sarscov
protein
eg
use
rabi
viru
vesicular
stomat
viru
bovin
parainfluenza
viru
type
adenoviru
attenu
vaccinia
viru
mva
vector
well
mice
immun
dna
vaccin
express
protein
gene
develop
neutral
antibodi
sarscov
protect
sarscov
challeng
tabl
display
overview
vaccin
test
efficaci
anim
model
inactiv
sar
vaccin
report
elicit
high
titer
proteinspecif
neutral
antibodi
studi
howev
address
whether
inactiv
whole
sarscov
virion
confer
protect
viru
challeng
mice
immun
twice
candid
sarscov
vaccin
produc
twostep
inactiv
procedur
involv
sequenti
formaldehyd
uv
inactiv
develop
highantibodi
titer
sarscov
protein
high
level
neutral
antibodi
spruth
et
al
see
chapter
moreov
vaccin
confer
protect
immun
demonstr
prevent
sarscov
replic
respiratori
tract
mice
intranas
challeng
sarscov
protect
mice
correl
antibodi
titer
sarscov
protein
neutral
antibodi
titer
similar
result
obtain
use
betapropiolacton
inactiv
sarscov
vaccin
mice
addit
two
chines
group
demonstr
protect
efficaci
inactiv
sar
vaccin
rhesu
monkey
qin
et
al
zhou
et
al
solubl
recombin
polypeptid
contain
ntermin
segment
glycoprotein
may
suffic
induc
neutral
antibodi
protect
immun
mice
bisht
et
al
addit
trimer
recombin
protein
abl
elicit
efficaci
protect
immun
respons
hamster
kam
et
al
one
promis
vaccin
candid
base
combin
recombin
protein
protollin
adjuv
young
age
mice
intranas
protollinformul
protein
seroconvers
usual
occur
week
ill
virusneutr
antibodi
detect
convalesc
human
serum
patient
recov
sarsneutr
antibodi
titer
peak
month
undetect
patient
month
cao
et
al
neutral
antibodi
may
direct
differ
region
protein
monoclon
antibodi
epitop
exert
potent
neutral
sarscov
vitro
sui
et
al
lip
et
al
convers
peptid
locat
region
abl
induc
neutral
antibodi
bisht
et
al
keng
et
al
zhang
et
al
although
experi
divers
anim
model
reveal
rel
low
level
neutral
antibodi
exert
potent
protect
lower
respiratori
tract
infect
neutral
antibodi
titer
necessari
achiev
protect
human
expos
sarscov
known
concern
case
reemerg
sar
possibl
absenc
cross
protect
virus
howev
recent
studi
et
al
shown
neutral
epitop
sarscov
maintain
crossspeci
transmiss
suggest
receptor
bind
domainbas
vaccin
may
induc
broad
protect
human
anim
sarscov
variant
sar
autopsi
extens
necrosi
spleen
atrophi
white
pulp
sever
lymphocyt
deplet
observ
hand
rapid
phase
peripher
lymphocyt
recoveri
usual
coincid
improv
clinic
condit
sar
patient
peiri
et
al
longliv
memori
cell
respons
sarscov
nucleocapsid
protein
demonstr
recov
sar
patient
although
relev
antivir
protect
well
understood
peng
et
al
li
et
al
howev
despit
potent
immun
respons
clinic
recoveri
peripher
lymphocyt
count
recov
patient
restor
normal
level
interestingli
mice
lack
nkt
cell
nk
cell
b
cell
clear
viru
day
infect
glass
et
al
data
argu
cellmedi
immun
respons
essenti
control
viru
clearanc
vaccin
elicit
high
level
antigenspecif
igg
serum
signific
level
antigenspecif
lung
iga
hu
et
al
contrast
mice
immun
intramuscularli
alum
absorb
protein
develop
detect
iga
respons
follow
viru
challeng
age
mice
viru
detect
lung
mice
vaccin
intranas
wherea
intramuscularli
immun
mice
show
signific
control
viru
replic
compar
control
hu
et
al
dna
vaccin
encod
glycoprotein
sarscov
induc
cell
neutral
antibodi
respons
protect
immun
mous
model
author
also
demonstr
antibodi
respons
mice
vaccin
express
vector
encod
form
protein
includ
transmembran
domain
elicit
neutral
antibodi
viral
replic
reduc
six
order
magnitud
lung
mice
vaccin
protein
plasmid
dna
express
vector
protect
mediat
humor
tcelldepend
immun
mechan
subsequ
studi
use
primeboost
combin
dna
whole
kill
sarscov
vaccin
elicit
higher
antibodi
respons
dna
whole
kill
viru
vaccin
alon
apart
studi
sever
group
analyz
immunogen
sar
dna
vaccin
none
challeng
vaccin
anim
sarscov
adenovirusvector
base
vaccin
strategi
sarscov
employ
earli
sar
outbreak
demonstr
vaccin
rhesu
macaqu
develop
virusneutr
antibodi
respons
fragment
protein
cell
respons
nucleocapsid
gao
et
al
recent
see
et
al
demonstr
vaccin
mice
adenoviru
type
nucleocapsid
administ
intranas
intramuscularli
significantli
limit
sarscov
replic
lung
vaccin
reduct
pulmonari
sarscov
titer
compar
control
anim
dinapoli
et
al
final
venezuelan
equin
enceph
viru
base
vaccin
test
extens
young
age
mice
importantli
differ
recombin
sarscov
bear
epidem
zoonot
protein
variant
use
challeng
vaccin
mice
venezuelan
equin
enceph
viru
replicon
particl
express
epidem
urbani
sarscov
strain
glycoprotein
particl
contain
nucleocapsid
protein
strain
provid
complet
shortand
longterm
protect
homolog
strain
challeng
young
senesc
mice
deme
et
al
although
protein
encod
vaccin
provid
complet
shortterm
protect
heterolog
strain
challeng
young
mice
limit
protect
seen
vaccin
senesc
anim
interestingli
nucleocapsidencod
vaccin
fail
protect
homolog
heterolog
challeng
also
result
enhanc
immunopatholog
eosinophil
infiltr
within
lung
sarscovchalleng
mice
deme
et
al
new
gener
vaccin
may
obtain
manipul
fulllength
infecti
cdna
clone
sarscov
one
approach
would
delet
orf
similar
coronaviru
mutant
gener
previous
mous
hepat
felin
infecti
periton
delet
virus
replic
extent
wildtyp
virus
vitro
sever
attenu
vivo
make
potenti
vaccin
candid
howev
sarscov
delet
mutant
lack
orf
grew
similar
parent
wildtyp
viru
mous
model
yount
et
al
hand
recombin
sarscov
lack
e
gene
attenu
vitro
vivo
viabl
recombin
viru
e
gene
delet
recov
vero
cell
titer
around
pfuml
titer
respiratori
tract
hamster
reduc
compar
wildtyp
sarscov
replic
suggest
mutant
attenu
multipl
virus
packag
cell
line
would
provid
miss
protein
tran
would
make
promis
sarscov
vaccin
candid
e
gene
delet
live
attenu
viru
vaccin
may
revert
wildtyp
recombin
circul
human
highli
attenu
modifi
vaccinia
viru
ankara
mva
use
express
glycoprotein
sarscov
vaccin
experi
use
mous
ferret
rhesu
monkey
model
bisht
et
al
chen
et
al
weingartl
et
al
intranas
intramuscular
administr
mva
encod
sarscov
protein
led
induct
humor
immun
respons
balbc
mice
well
reduc
viral
titer
respiratori
tract
bisht
et
al
recombin
bovinehuman
parainfluenza
viru
type
vector
develop
live
attenu
intranas
pediatr
vaccin
human
parainfluenza
viru
type
immun
african
green
monkey
singl
dose
express
sarscov
protein
administ
via
respiratori
tract
induc
product
sarscov
neutral
antibodi
recombin
express
sarscov
structur
protein
n
individu
combin
evalu
immunogen
protect
efficaci
hamster
absenc
protein
express
n
e
induc
detect
serum
sarscovneutr
antibodi
respons
protect
sarscov
challeng
respiratori
tract
wherea
vector
express
protein
induc
neutral
antibodi
respons
protect
recombin
rabi
viru
express
protein
sarscov
induc
neutral
antibodi
respons
mice
faber
et
al
similarli
attenu
vesicular
stomat
viru
vector
encod
sarscov
protein
may
use
induc
neutral
antibodi
respons
kapadia
et
al
mice
vaccin
recombin
vesicular
stomat
viru
express
protein
develop
sarscovneutr
antibodi
abl
control
challeng
sarscov
perform
either
month
month
singl
vaccin
addit
passiv
antibodi
transfer
experi
author
demonstr
antibodi
respons
induc
vaccin
suffici
control
sarscov
infect
efficaci
vector
demonstr
studi
use
age
mice
age
mice
vaccin
recombin
vesicular
stomat
viru
express
protein
antibodi
titer
induc
suffici
protect
subsequ
challeng
sarscov
vogel
et
al
african
green
monkey
immun
via
respiratori
tract
two
dose
recombin
newcastl
diseas
viru
encod
protein
develop
rel
high
titer
sarscov
neutral
antibodi
upon
challeng
demonstr
zoonot
coronavirus
order
prevent
propos
delet
essenti
gene
locat
posit
distant
gene
e
reloc
delet
gene
posit
previous
occupi
gene
e
enjuan
et
al
potenti
recombin
lead
rescu
gene
e
would
lead
loss
essenti
gene
altern
transcript
regulatori
sequenc
tr
vaccin
viru
could
genet
manipul
sequenc
incompat
tr
known
circul
coronaviru
describ
yount
et
al
viru
could
modifi
build
attenu
mutat
genet
backbon
recombin
resist
tr
rewir
viru
either
use
safe
high
titer
seed
stock
make
kill
vaccin
live
viru
vaccin
one
attenu
mutat
could
target
nonstructur
protein
recombin
mous
hepat
viru
mhv
encod
delet
sequenc
grew
normal
tissu
cultur
sever
attenu
vivo
et
al
low
dose
mutant
mhv
elicit
potent
cytotox
cell
respons
protect
mice
homolog
heterolog
viru
challeng
attenu
strategi
provid
new
paradigm
develop
highli
effici
coronaviru
vaccin
although
sever
type
vector
vaccin
develop
sever
compani
favor
classic
approach
use
inactiv
whole
viru
develop
vaccin
use
preclin
test
see
chapter
method
place
product
avail
vaccin
could
easili
use
use
wellestablish
technolog
preclin
develop
stage
prefer
differ
anim
speci
use
evalu
safeti
efficaci
candid
vaccin
overal
wide
rang
anim
speci
includ
rodent
mice
hamster
carnivor
ferret
cat
nonhuman
primat
cynomolgu
rhesu
macaqu
common
marmoset
african
green
monkey
experiment
infect
sarscov
robert
et
al
martina
et
al
kuiken
et
al
mcauliff
et
al
haagman
osterhau
speci
show
clinic
sign
diseas
although
viru
replic
effici
respiratori
tissu
age
mice
ferret
hand
show
sign
clinic
diseas
albeit
absenc
typic
lung
lesion
seen
human
sar
robert
et
al
contrast
inocul
sarscov
respiratori
tract
cynomolgu
macaqu
caus
infect
bronchial
epitheli
cell
pneumocyt
day
postinfect
follow
extens
pneumocyt
hyperplasia
lung
day
postinfect
haagman
osterhau
lesion
consist
multipl
foci
acut
diffus
alveolar
damag
character
flood
alveoli
proteinrich
edema
fluid
mix
variabl
number
neutrophil
quit
similar
observ
human
acut
stage
sar
remark
vaccin
candid
test
ferret
show
reduc
efficaci
vaccin
mva
encod
protein
induc
moder
antibodi
respons
consequ
protect
intranas
sarscov
infect
even
result
inflammatori
respons
liver
vaccin
ferret
weingartl
et
al
whether
aberr
respons
result
immunopatholog
mechan
like
antibodydepend
enhanc
infect
repres
recal
respons
viral
antigen
liver
clear
moment
deserv
investig
addit
limit
protect
sarscov
challeng
observ
ferret
vaccin
inactiv
whole
viru
darnel
et
al
two
four
ferret
show
littl
neutral
antibodi
even
second
immun
none
vaccin
ferret
abl
reduc
viru
excret
day
challeng
subsequ
clear
viru
rapidli
compar
control
anim
adenovirusbas
vaccin
test
ferret
seem
power
protect
lower
respiratori
tract
effici
less
effect
viru
excret
upper
respiratori
tract
kobing
et
al
five
year
first
sar
outbreak
rang
candid
vaccin
develop
earli
compani
china
us
initi
phase
trial
first
clinic
trial
initi
chines
compani
sinovac
biotech
beij
collabor
chines
academi
medic
scienc
use
inactiv
whole
viru
vaccin
evalu
safeti
immunogen
vaccin
subject
receiv
two
dose
vaccin
placebo
control
day
individu
show
seroconvers
peak
titer
neutral
antibodi
reach
week
second
vaccin
follow
clinic
trial
iii
viru
vaccin
type
coronaviru
felin
infecti
periton
viru
fipv
subsequ
expos
fipv
infect
weiss
scott
macrophag
abl
take
felin
coronavirusantibodi
complex
effici
caus
viru
replic
higher
titer
interestingli
one
studi
also
demonstr
antibodi
human
sarscov
isol
enhanc
entri
pseudotyp
virus
express
civet
cat
sarslik
cov
protein
cell
replic
yang
et
al
date
evid
enhanc
replic
follow
sarscov
challeng
previous
immun
anim
one
problem
may
aris
vaccin
whole
inactiv
viru
absorb
certain
adjuv
alum
could
relat
induct
skew
recal
respons
similar
observ
children
vaccin
inactiv
respiratori
syncyti
measl
viru
vaccin
although
much
effort
focus
develop
sar
vaccin
commerci
viabil
develop
vaccin
sarscov
ultim
depend
whether
viru
reemerg
near
futur
question
whether
possibl
futur
outbreak
caus
major
outbreak
vaccin
antivir
passiv
immun
would
relev
context
protect
highrisk
individu
laboratori
healthcar
worker
five
year
first
sar
outbreak
sever
candid
sarscov
vaccin
variou
stage
preclin
clinic
develop
base
observ
sarscov
infect
effici
control
upon
passiv
transfer
antibodi
direct
protein
sarscov
vaccin
encod
protein
develop
anim
immun
divers
vaccin
contain
protein
protein
gene
develop
sarscovneutr
antibodi
protect
sarscov
challeng
futur
challeng
develop
sarscov
vaccin
link
potenti
reemerg
viru
vaccin
abl
induc
highli
crossreact
antibodi
effici
protect
gastrointestin
respiratori
tract
need
given
fact
previou
outbreak
mainli
elderli
human
succumb
infect
special
attent
given
protect
specif
individu
signific
declin
week
later
lin
et
al
sever
candid
sar
vaccin
variou
stage
preclin
clinic
develop
sar
patient
recov
high
level
neutral
antibodi
respons
observ
suggest
antibodi
respons
play
role
determin
ultim
diseas
outcom
sarscovinfect
patient
although
attempt
made
test
efficaci
serum
prepar
seroconvalesc
sar
patient
acut
phase
sar
conclus
evid
obtain
regard
efficaci
mice
hand
sarscov
infect
effici
control
upon
passiv
transfer
convalesc
immunoglobulin
concept
antibodi
protect
sar
explor
gener
human
monoclon
antibodi
sarscov
prophylact
administr
human
monoclon
antibodi
reduc
replic
sarscov
lung
infect
ferret
complet
prevent
develop
sarscovinduc
macroscop
lung
patholog
abolish
shed
viru
pharyng
secret
ter
meulen
et
al
subsequ
studi
sever
monoclon
antibodi
evalu
efficaci
mous
hamster
model
sui
et
al
traggiai
et
al
import
assess
immunogen
candid
sarscov
vaccin
use
viru
neutral
assay
well
acknowledg
varieti
test
use
signific
problem
sinc
time
consensu
sensit
specif
reproduc
assay
system
compar
data
candid
vaccin
requir
intern
standard
immunolog
assay
avail
antibodi
standard
use
evalu
vaccin
test
cross
reactiv
antibodi
gener
vaccin
murin
leukemia
viru
use
gener
infecti
particl
contain
differ
protein
girogl
et
al
enhanc
diseas
mortal
observ
kitten
immun
infect
